|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ALNY 10-K filed Feb 26, 2010. Technology
License Commitments
The Company has licensed from third parties the rights to use
certain technologies in its research process as well as in any
products the Company may develop including these licensed
technologies. In accordance with the related license agreements,
the Company is required to make certain fixed payments to the
licensor or a designee of the licensor over various agreement
terms. Many of these agreement terms are consistent with the
remaining lives of the underlying intellectual property that the
Company has licensed. At December 31, 2009, the Company was
committed to make the following fixed, cancellable payments
under existing license agreements, in thousands:
Table of Contents
ALNYLAM
PHARMACEUTICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS —
(Continued)
These excerpts taken from the ALNY 10-K filed Mar 2, 2009. Technology
License Commitments
The Company has licensed from third parties the rights to use
certain technologies in its research process as well as in any
products the Company may develop including these licensed
technologies. In accordance with the related license agreements,
the Company is required to make certain fixed payments to the
licensor or a designee of the licensor over various agreement
terms. Many of these agreement terms are consistent with the
remaining lives of the underlying intellectual property that the
Company has licensed. At December 31, 2008, the Company was
committed to make the following fixed license payments under
existing license agreements, in thousands:
Technology License Commitments The Company has licensed from third parties the rights to use certain technologies in its research process as well as in any products the Company may develop including these licensed technologies. In accordance with the related license agreements, the Company is required to make certain fixed payments to the licensor or a designee of the licensor over various agreement terms. Many of these agreement terms are consistent with the remaining lives of the underlying intellectual property that the Company has licensed. At December 31, 2008, the Company was committed to make the following fixed license payments under existing license agreements, in thousands:
These excerpts taken from the ALNY 10-K filed Mar 10, 2008. Technology
License Commitments
The Company has licensed the rights to use certain technologies
in its research process as well as in any products the Company
may develop including these licensed technologies. In accordance
with the related license agreements, the Company is required to
make certain fixed payments to the licensor or a designee of the
licensor over various agreement terms. Many of these agreement
terms are consistent with the remaining lives of the underlying
intellectual property that the Company has licensed. At
December 31, 2007, the Company was committed to make the
following fixed license payments under existing license
agreements, in thousands:
In January 2007, Tekmira Pharmaceuticals Corporation
(“Tekmira”), formerly Inex Pharmaceuticals, Inc.,
granted the Company an exclusive license to its liposomal
delivery formulation technology for the discovery, development
and commercialization of RNAi therapeutics. In connection with
Tekmira’s license grant, the Company agreed to make
available to Tekmira a $5.0 million loan for capital
equipment expenditures related to manufacturing services
performed by Tekmira beginning in 2008.
Technology License Commitments The Company has licensed the rights to use certain technologies in its research process as well as in any products the Company may develop including these licensed technologies. In accordance with the related license agreements, the Company is required to make certain fixed payments to the licensor or a designee of the licensor over various agreement terms. Many of these agreement terms are consistent with the remaining lives of the underlying intellectual property that the Company has licensed. At December 31, 2007, the Company was committed to make the following fixed license payments under existing license agreements, in thousands:
In January 2007, Tekmira Pharmaceuticals Corporation (“Tekmira”), formerly Inex Pharmaceuticals, Inc., granted the Company an exclusive license to its liposomal delivery formulation technology for the discovery, development and commercialization of RNAi therapeutics. In connection with Tekmira’s license grant, the Company agreed to make available to Tekmira a $5.0 million loan for capital equipment expenditures related to manufacturing services performed by Tekmira beginning in 2008. This excerpt taken from the ALNY 10-K filed Mar 12, 2007. Technology
License Commitments
The Company has licensed the rights to use certain technologies
in its research process as well as in any products the Company
may develop including these licensed technologies. In accordance
with the related license agreements, the Company is required to
make certain fixed annual payments to the licensor or a designee
of the licensor over various agreement terms. Many of these
agreement terms are consistent with the remaining lives of the
underlying intellectual property that the Company has licensed.
At December 31, 2006, the Company was committed to make the
following fixed license payments under existing license
agreements, in thousands:
This excerpt taken from the ALNY 10-K filed Mar 16, 2006. Technology
License Commitments
The Company has licensed the rights to use certain technologies
in its research process as well as in any products the Company
may develop including these licensed technologies. In accordance
with the related license agreements, the Company is required to
make certain fixed annual payments to the licensor or a designee
of the licensor over various agreement terms. Many of these
agreement terms are consistent with the remaining lives of the
underlying intellectual property that the Company has licensed.
At December 31, 2005, the Company was committed to make the
following fixed license payments under existing license
agreements, in thousands:
| EXCERPTS ON THIS PAGE:
RELATED TOPICS for ALNY: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
